Xeris Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Chicago IL United States (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2013
NCT01972152
First Marketed Drug
2005
diclofenamide
First NDA Approval
2021
levoketoconazole (Recorlev)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

XERIS | Xeris Pharmaceuticals | Xeris Pharmaceuticals, Inc.